Approval news is pending. Soros bought $75M this summer. The stock had a wild ride ($25-$55 range this year) and just a couple of bucks a couple of years back. http://blog.t3live.com/2010/11/dendreons-dndn-fate-hangs-in-balance-of.html
i did not spend much time reading on that but Soros had shares on Sep 30. i assume he bought them within 3 month, probably when the market was going into tailspin. he could be out of the stock by now. all we can really say is that he has expressed genuine interest in the stock.
The Medicare advisory panel voted today in favor of Provenge coverage, Dendreon Corporation's (DNDN) prostate cancer drug. The panel recommends that Medicare cover the treatment based on its survival benefits. The vote was 3.4 on a 5-point scale in favor and paves the way for the Medicare to offer coverage of the $93,000 treatment. There is always the chance Medicare could reject coverage or request more information but these panel recommendations are typically followed. Shares of DNDN are still halted as the news disseminates. Yet this a great hurdle mounted. The final decision will be made in June 2011. http://blog.t3live.com/2010/11/dendreon-dndn-follow-up-panel-votes-in.html $93K is pretty steep! talk about INFLATION!!!